• 1

    Walsh SM, Fischer SG, Sage RA: Survival of patients with primary pedal melanoma. J Foot Ankle Surg 42: 193, 2003.

  • 2

    Anbari KK, Schuchter LM, Bucky LP, et al: Melanoma of unknown primary site. Cancer 79: 1816, 1997.

  • 3

    Schlagenhauff B, Stroebel W, Ellwanger U, et al: Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma. Cancer 80: 60, 1997.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Bae JM, Choi YY, Kim DS, et al: Metastatic melanomas of unknown primary show a better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 72: 59, 2015

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 5

    Greene FL, Trotti A, Fritz AG, et al, eds. AJCC Cancer Staging Handbook, 7th Ed, American Joint Committee on Cancer, Chicago, 2010.

  • 6

    Barnes BC, Seigler HF, Saxby TS, et al: Melanoma of the foot. J Bone Joint Surg Am 76: 892, 1994.

  • 7

    Day CL, Sober AJ, Kopf AW, et al: A prognostic model for clinical stage I melanoma of the lower extremity: location on foot as independent risk factor for recurrent disease. Surgery 89: 599, 1981.

    • Search Google Scholar
    • Export Citation
  • 8

    Fortin PT, Freiberg AA, Rees R, et al: Malignant melanoma of the foot and ankle. J Bone Joint Surg Am 77: 1396, 1995.

  • 9

    Garbe C, Buttner P, Bertz J, et al: Primary cutaneous melanoma: prognostic classification of anatomic location. Cancer 75: 2492, 1995.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Wong JH, Cagle LA, Morton DL: Surgical treatment of lymph nodes with metastatic melanoma from unknown primary site. Arch Surg 122: 1380, 1987.

  • 11

    Van der Ploeg PA, Haydu LE, Spillane AJ, et al: Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. Ann Surg Oncol 21: 3108, 2014.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 12

    Lee C, Faries M, Wanek L, et al: Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27: 3489, 2009.

  • 13

    Weide B, Faller C, Elsasser M, et al: Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour. PLoS One 8: e66953, 2013.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation
  • 14

    Van Beek E, Balm A, Nieweg O, et al: Treatment of regional metastatic melanoma of unknown primary origin. Cancers (Basel) 7: 1543, 2015.

  • 15

    Luke J, Ott P: PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget 6: 3479, 2015.

  • 16

    Egberts F, Bergner I, Kruger S, et al: Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol 25: 246, 2014.

    • Crossref
    • PubMed
    • Web of Science
    • Search Google Scholar
    • Export Citation

Metastatic Melanoma of a Metatarsal

A Case Report

Gary Friend North Shore Foot and Ankle, Glenview, IL.

Search for other papers by Gary Friend in
Current site
Google Scholar
PubMed
Close
 DPM
and
Jeffrey Mitchell North Shore Foot and Ankle, Glenview, IL.

Search for other papers by Jeffrey Mitchell in
Current site
Google Scholar
PubMed
Close
 DPM
Restricted access

A 53-year-old woman presented with painful swelling of the right forefoot presenting clinically as a metatarsal stress fracture. Radiographs showed destructive changes, and diagnostic imaging revealed an aggressive neoplasm. The lesion was biopsied, and the pathologic diagnosis was metastatic melanoma. A thorough physical examination and advanced imaging did not reveal a primary tumor. Ray resection was performed with en bloc resection of the neoplasm. The patient continues to receive long-term immune stimulation chemotherapy 34 months after the ray resection.

Corresponding author: Gary Friend, DPM, North Shore Foot and Ankle, 2501 Compass Rd, Ste 120, Glenview, IL 60026. (E-mail: gjfriend@gmail.com)